Tender detail
Open-house discount agreements for pegfilgrastim 2026-05
Summary
The participating health insurers are seeking discount agreements for the active ingredient pegfilgrastim with all suitable pharmaceutical companies under an open-house procedure with uniform terms and no exclusivity. The agreements may run for up to 24 months from 1 May 2026 and end no later than 30 April 2028; companies may join at any time during the contract period.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.